Table 2 Correlation between clinicopathologic features and TROP2 expression in TNBC patients

Cohort 1

Low (%)

High (%)

 Age (yr)

.107

   < 50

426 (59.6)

176 (56.2)

250 (62.2)

   ≥ 50

289 (40.4)

137 (43.8)

152 (37.8)

 Nuclear grade

.199

  1–2

184 (25.7)

88 (28.1)

96 (23.9)

  3

531 (74.3)

225 (71.9)

306 (76.1)

 Histologic grade

.477

  1–2

178 (24.9)

82 (26.2)

96 (23.9)

  3

537 (75.1)

231 (73.8)

306 (76.1)

 Histologic type

.825

  IBC-NST

596 (83.4)

262 (83.7)

34 (83.1)

  Non-IBC-NST

119 (16.6)

51 (16.3)

68 (16.9)

 pT

.578

  1–2

689 (96.4)

303 (96.8)

386 (96.0)

  3–4

26 (3.6)

10 (3.2)

16 (4.0)

 LN status

.945

  Negative

467 (65.3)

204 (65.2)

263 (65.4)

  Positive

248 (34.7)

109 (34.8)

139 (34.6)

 LVI

.989

  Negative

537 (75.1)

235 (75.1)

302 (75.1)

  Positive

178 (24.9)

78 (24.9)

100 (24.9)

 Stage

.936

  1

241 (33.7)

105 (33.5)

136 (33.8)

  2–3

474 (66.3)

208 (66.5)

266 (66.2)

 TILs (%)

.638

   < 10

169 (23.6)

79 (25.2)

90 (22.4)

  10–59

320 (44.8)

139 (44.4)

181 (45.0)

  60–100

226 (31.6)

95 (30.4)

131 (32.6)

Cohort 2

Low (%)

High (%)

 Age (yr)

.439

   < 50

51 (77.3)

15 (71.4)

36 (80.0)

   ≥ 50

15 (22.7)

6 (28.6)

9 (20.0)

 Nuclear grade

.955

  2

16 (24.2)

5 (23.8)

11 (24.4)

  3

50 (75.8)

16 (76.2)

34 (75.6)

 Histologic grade

.979

  2

19 (28.8)

6 (28.6)

13 (28.9)

  3

47 (71.2)

15 (71.4)

32 (71.1)

 Histologic type

.683

  IBC-NST

61 (92.4)

19 (90.5)

42 (93.3)

  Non-IBC-NST

5 (7.6)

2 (9.5)

3 (6.7)

 ypT

.637

  1–2

57 (87.7)

19 (90.5)

38 (86.4)

  3–4

8 (12.3)

2 (9.5)

6 (13.6)

 LN status

.883

  Negative

40 (60.6)

13 (61.9)

27 (60.0)

  Positive

26 (39.4)

8 (38.1)

26 (39.4)

 LVI

.714

  Negative

46 (69.7)

14 (66.7)

32 (71.1)

  Positive

20 (30.3)

7 (33.3)

13 (28.9)

 Stage

.547

  1

31 (47.0)

11 (52.4)

20 (44.4)

  2–3

35 (53.0)

10 (47.6)

25 (55.6)

 TILs (%)

.811

   < 10

35 (53.0)

10 (47.6)

25 (55.6)

  10–59

26 (39.4)

9 (42.9)

17 (37.8)

  60–100

5 (7.6)

2 (9.5)

3 (6.7)

 RCB class

.110

  1

2 (3.0)

2 (9.5)

0

  2

44 (66.7)

13 (61.9)

31 (68.9)

  3

20 (30.3)

6 (28.6)

14 (31.1)

 Miller-Payne grade

.660

  1

2 (3.0)

1 (4.8)

1 (2.2)

  2

12 (18.2)

3 (14.3)

9 (20.0)

  3

32 (48.5)

10 (47.6)

22 (48.9)

  4

20 (30.3)

7 (33.3)

13 (28.9)

Cohort 3

Low (%)

High (%)

 Age (yr)

.837

   < 50

18 (69.2)

6 (66.7)

12 (70.6)

   ≥ 50

8 (30.8)

3 (33.3)

5 (29.4)

 TILs (%)

.186

   < 2

7 (26.9)

1 (11.1)

6 (35.3)

   ≥ 2

19 (73.1)

8 (88.9)

11 (64.7)

 Site

.299

  Lung

12 (46.2)

5 (55.6)

7 (41.2)

  Brain

11 (42.3)

2 (22.2)

9 (52.9)

  Bone

2 (7.7)

1 (11.1)

1 (5.9)

  Soft tissue

1 (3.8)

1 (11.1)

0